Tildrakizumab in the treatment of psoriasis – literature review
Psoriasis is a chronic, inflammatory disease. The incidence of its occurrence in developed countries is 1–4%. The aim of this study is to present the current state of knowledge and characterize the antibody tildrakizumab, which in March 2018 was approved by the FDA agency for use in adult patients w...
Main Author: | Katarzyna Banaszczyk |
---|---|
Format: | Article |
Language: | English |
Published: |
Termedia Publishing House
2019-08-01
|
Series: | Rheumatology |
Subjects: | |
Online Access: | https://www.termedia.pl/Tildrakizumab-in-the-treatment-of-psoriasis-literature-review,18,37542,1,1.html |
Similar Items
-
Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting
by: Martina Burlando, et al.
Published: (2021-05-01) -
Profile of tildrakizumab-asmn in the treatment of moderate-to-severe plaque psoriasis: evidence to date
by: Beck KM, et al.
Published: (2018-08-01) -
Tildrakizumab: An Evidence-Based Review of Its Use in the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis
by: Näslund-Koch C, et al.
Published: (2020-09-01) -
Tildrakizumab ineffective in generalized granuloma annulare
by: Eingun James Song, MD
Published: (2021-01-01) -
A Review of the Efficacy and Safety for Biologic Agents Targeting IL-23 in Treating Psoriasis With the Focus on Tildrakizumab
by: Feras M. Ghazawi, et al.
Published: (2021-08-01)